Orano Med

Orano Med company information, Employees & Contact Information

Explore related pages

Related company profiles:

Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope.  Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer.  The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products.  For more information please visit www.macrocyclics.com.

Company Details

Employees
190
Founded
-
Address
700 Klein Road, Plano,tx 75074,united States
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Plano, TX
Looking for a particular Orano Med employee's phone or email?

Orano Med Questions

News

Orano Med Inaugurates Expansion of its U.S. Research and Development Center in Texas - Business Wire

Orano Med Inaugurates Expansion of its U.S. Research and Development Center in Texas Business Wire

Orano Med Achieves Key Milestone in French ATEF Facility Construction, an Essential Asset for Large-Scale Production of Innovative Lead-212-based Therapies - Yahoo Finance

Orano Med Achieves Key Milestone in French ATEF Facility Construction, an Essential Asset for Large-Scale Production of Innovative Lead-212-based Therapies Yahoo Finance

Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025 - The Manila Times

Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025 The Manila Times

Orano Med breaks ground on $265M thorium production site - Radiology Business

Orano Med breaks ground on $265M thorium production site Radiology Business

After US plant reveal, France's Orano Med lays out €250M to build another radioligand facility overseas - Fierce Pharma

After US plant reveal, France's Orano Med lays out €250M to build another radioligand facility overseas Fierce Pharma

Orano Med wins the "Innovation of the Year" award at the Grand Dîner de L'Usine Nouvelle - orano.group

Orano Med wins the "Innovation of the Year" award at the Grand Dîner de L'Usine Nouvelle orano.group

Orano Med Lays Foundations for Its New Facility to Produce Precursors for Its Future Lead-212 Radioligand Therapies - Yahoo Finance

Orano Med Lays Foundations for Its New Facility to Produce Precursors for Its Future Lead-212 Radioligand Therapies Yahoo Finance

Sanofi and radioligand partner Orano Med report mid-stage win in rare tumor - Endpoints News

Sanofi and radioligand partner Orano Med report mid-stage win in rare tumor Endpoints News

Is 212Pb Really Happening? The Post-177Lu/225Ac Blockbuster? - Journal of Nuclear Medicine

Is 212Pb Really Happening? The Post-177Lu/225Ac Blockbuster? Journal of Nuclear Medicine

Orano Med’s Alpha Therapy Laboratory ((ATLab), Onnaing, France - Pharmaceutical Technology

Orano Med’s Alpha Therapy Laboratory ((ATLab), Onnaing, France Pharmaceutical Technology

Orano Med inaugurates Pb-212 production facility in Indiana - American Nuclear Society

Orano Med inaugurates Pb-212 production facility in Indiana American Nuclear Society

Sanofi Inks $326M Radiopharma Deal With Orano - BioSpace

Sanofi Inks $326M Radiopharma Deal With Orano BioSpace

Sanofi and Orano Med partner for radioligand therapy development - Pharmaceutical Technology

Sanofi and Orano Med partner for radioligand therapy development Pharmaceutical Technology

France's Orano Med debuts radiotherapy manufacturing plant near Indianapolis - Fierce Pharma

France's Orano Med debuts radiotherapy manufacturing plant near Indianapolis Fierce Pharma

Orano Med Announces Appointment of Dr. Volker Wagner as Chief Medical Officer - orano.group

Orano Med Announces Appointment of Dr. Volker Wagner as Chief Medical Officer orano.group

Orano Announces Leadership Transition in Orano Med - Yahoo Finance

Orano Announces Leadership Transition in Orano Med Yahoo Finance

RadioMedix and Orano Med Complete Patient Enrolment in Phase II Trial of Targeted Alpha-Emitter AlphaMedix in Neuroendocrine Cancers - Business Wire

RadioMedix and Orano Med Complete Patient Enrolment in Phase II Trial of Targeted Alpha-Emitter AlphaMedix in Neuroendocrine Cancers Business Wire

Orano Med Starts Phase I Trial With Alpha Radioligand Therapy 212Pb-GRPR in Patients With Solid Tumors - Business Wire

Orano Med Starts Phase I Trial With Alpha Radioligand Therapy 212Pb-GRPR in Patients With Solid Tumors Business Wire

RadioMedix and Orano Med receive FDA Breakthrough Therapy Designation for AlphaMedix - Business Wire

RadioMedix and Orano Med receive FDA Breakthrough Therapy Designation for AlphaMedix Business Wire

Sanofi returns to Orano with €300M for radioligand 'pioneer' project - Fierce Biotech

Sanofi returns to Orano with €300M for radioligand 'pioneer' project Fierce Biotech

Sanofi and Orano Med partner to advance radioligand therapies for rare cancers - PMLiVE

Sanofi and Orano Med partner to advance radioligand therapies for rare cancers PMLiVE

News | The Hive attracts Orano Med to Villejuif - CoStar

News | The Hive attracts Orano Med to Villejuif CoStar

Sanofi invests €300m in Orano Med's lead-based radioligands - pharmaphorum

Sanofi invests €300m in Orano Med's lead-based radioligands pharmaphorum

SNY Inks Deal With Orano Med for Next-Generation Radioligand Therapies - Nasdaq

SNY Inks Deal With Orano Med for Next-Generation Radioligand Therapies Nasdaq

Radiomedix and Orano Med Announce the Initiation of the - GlobeNewswire

Radiomedix and Orano Med Announce the Initiation of the GlobeNewswire

Radiopharma boom continues as Orano Med builds major facility | Pharmaceutical | The Pharmaletter - The Pharma Letter

Radiopharma boom continues as Orano Med builds major facility | Pharmaceutical | The Pharmaletter The Pharma Letter

Sanofi Dips Into Red-Hot Radiopharma Space With $110M Licensing Deal - BioSpace

Sanofi Dips Into Red-Hot Radiopharma Space With $110M Licensing Deal BioSpace

Molecular Partners and Orano Med collaborate to develop novel Radio-DARPin therapeutics - World Business Outlook

Molecular Partners and Orano Med collaborate to develop novel Radio-DARPin therapeutics World Business Outlook

Sanofi partners with RadioMedix and Orano Med to develop AlphaMedix - World Pharmaceutical Frontiers

Sanofi partners with RadioMedix and Orano Med to develop AlphaMedix World Pharmaceutical Frontiers

Sanofi, RadioMedix and Orano Med partner to develop rare cancer therapy in deal worth €320m - PMLiVE

Sanofi, RadioMedix and Orano Med partner to develop rare cancer therapy in deal worth €320m PMLiVE

Construction of major radioligand therapy manufacturing site begins - European Pharmaceutical Review

Construction of major radioligand therapy manufacturing site begins European Pharmaceutical Review

Orano Med and RadioMedix announce dosing of first patients in AlphaMedix™ Phase 1 clinical trial - GlobeNewswire

Orano Med and RadioMedix announce dosing of first patients in AlphaMedix™ Phase 1 clinical trial GlobeNewswire

Top Orano Med Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant